详见公司于2025年5月27日在上海证券交易所网站（www.sse.com.cn）披露 的《新华医疗关于公司控股股东增持公司股份计划的公告》（公告编号：临 2025-026）。 二、贷款承诺函的主要内容 工商银行山东省分行已为山东健康集团出具《上市公司股票增持贷款承诺 函》，同意为山东健康集团增持公司A股股票提供专项贷款支持，贷款金额不超 过人民币18,000万元，贷款期限不超过3年。 证券代码：600587 证券简称：新华医疗 公告编号：临 2025-027 山东新华医疗器械股份有限公司 关于控股股东取得增持股份专项贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）收到 控股股东山东颐养健康产业发展集团有限公司（以下简称"山东健康集团"）通 知，山东健康集团已获得中国工商银行股份有限公司山东省分行（以下简称"工 商银行山东省分行"）出具的《上市公司股票增持贷款承诺函》。工商银行山东 省分行拟为山东健康集团增持公司股份计划提供不超过人民币18, ...

Industry Overview - The dental medical equipment industry is experiencing rapid growth in China, driven by an aging population and increasing disposable income, leading to heightened awareness of oral health [1][8] - The market size for dental medical equipment in China is projected to grow from 22.3 billion yuan in 2020 to 41.2 billion yuan in 2024, with a compound annual growth rate (CAGR) of 16.59% [1][8] - The global dental medical equipment market is also expanding, expected to increase from 14.6 billion USD in 2020 to 20.7 billion USD in 2024, with a CAGR of 9.12% [6] Market Dynamics - The demand for dental medical services is rising, leading to a robust growth phase for the dental equipment market in China [1][8] - The domestic market for dental medical equipment is forecasted to reach 47.9 billion yuan by 2025 [1][8] - The domestic CBCT (Cone Beam Computed Tomography) market is becoming a focal point, with the localization rate expected to rise from 16.3% in 2020 to 56.44% in 2024 [10][18] Competitive Landscape - Major players in the Chinese dental medical equipment market include Xinhua Medical, Meiya Optoelectronics, Times Angel, and Kangzhong Medical [2][12] - The industry is currently reliant on imports for 90% of its dental equipment, particularly in the mid-to-high-end segments, but there is a significant opportunity for domestic companies to replace imports [12][18] - Key products from leading companies include CBCT systems, dental sterilization equipment, and implant devices [14][16] Development Trends - There is a notable acceleration in domestic replacement and technological breakthroughs, particularly in CBCT, with expectations for further advancements in high-end sectors [18] - The integration of digital and intelligent technologies is transforming the dental medical equipment industry, enhancing diagnostic efficiency and patient experience [19] - The market is witnessing a segmentation in demand, with older populations driving the need for dental implants and younger consumers pushing for aesthetic treatments like invisible orthodontics [20]

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

Group 1 - The controlling shareholder of Shandong Xinhua Medical Instrument Co., Ltd. plans to increase its stake in the company, currently holding 175,385,227 shares, which accounts for 28.91% of the total share capital of 606,677,919 shares [2][3] - The increase plan aims to invest no less than RMB 100 million and no more than RMB 200 million within 12 months through the Shanghai Stock Exchange [2][3] - If the shareholding ratio reaches or exceeds 30%, the controlling shareholder will apply to the China Securities Regulatory Commission for exemption from making a tender offer [2][4] Group 2 - A subsidiary of the company has received a Class III medical device registration certificate for a dialysis fluid filter, which is designed to remove endotoxins, bacteria, and insoluble particles from dialysis fluid [7][8] - The product has a filtration rate of ≥1000 ml/min and meets strict microbial and endotoxin removal standards, enhancing the safety and quality of dialysis treatment [9] - The introduction of this product enriches the company's blood purification product line, potentially improving its core competitiveness in the market [9]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have announced significant developments, providing insights for investors [2] Group 1: Company Announcements - Shenghong Technology has preliminarily set the inquiry transfer price at 65.85 CNY per share, with 24 institutional investors participating and a total of 25.73 million shares to be transferred [3] - Foton Motor plans to establish a joint venture with EVE Energy, investing 500 million CNY to expand its new energy heavy truck business, with a 50% ownership stake [4] - Jiadu Technology disposed of 7.6647 million shares of CloudWalk Technology, realizing a post-tax investment loss of 16.29 million CNY, which is 14.18% of its 2024 net profit [6] - Chongqing Steel has decided to terminate the absorption merger of its wholly-owned subsidiary, believing that independent operation will better leverage its logistics capabilities [8] - Ha Welding Communication's products can be used in controllable nuclear fusion projects, but the revenue from this sector is currently minimal [9] Group 2: Shareholding Changes - Xinhua Medical's controlling shareholder plans to increase its stake in the company by 100 million to 200 million CNY within the next 12 months [10] Group 3: Major Contracts - Pingzhi Information signed a framework agreement for AI computing power technology services with China Telecom, totaling approximately 246 million CNY, which will not significantly impact the company's annual performance [12]

Group 1: Company Leadership Changes - Longi Green Energy announced that Li Zhenguo will resign from the positions of General Manager and Legal Representative to focus on R&D and technology management, while continuing as the head of the Central Research Institute and Chief Technology Officer [2] - The company appointed Zhong Baoshan as the new General Manager, and this leadership change is not expected to impact the company's operations [2] Group 2: Contracts and Agreements - Pingzhi Information signed an AI computing power technology service framework agreement with China Telecom's Shaanxi branch, with a total contract value of approximately 246 million yuan [3] - The actual execution amount will depend on specific orders, and the agreement is not expected to have a significant impact on the company's annual performance [3] Group 3: Share Issuance and Stock Transactions - *ST Songfa announced the issuance of 738 million new shares at a price of 10.16 yuan per share for asset acquisition [5] - Shenghong Technology set the preliminary inquiry transfer price at 65.85 yuan per share, with 24 institutional investors participating in the inquiry [3] Group 4: Shareholder Actions - Xinhua Medical's controlling shareholder plans to increase holdings by 100 million to 200 million yuan [6] - Several companies, including Yongmaotai and Green Harmony, announced plans for share reductions by up to 3% of total shares [6] Group 5: Corporate Developments - Rongsheng Environmental Protection reported that its controlling shareholder, Feng Ronghua, has been taken into custody by law enforcement, but this matter is unrelated to the company [4] - Chongqing Steel terminated the absorption merger with its wholly-owned subsidiary [7]

Group 1 - Shenghong Technology has preliminarily determined the inquiry transfer price at 65.85 yuan per share, with 24 institutional investors participating and a total of 25.73 million shares to be transferred [1] - Foton Motor plans to establish a new energy technology company with EVE Energy, investing 500 million yuan to enhance its new energy heavy truck business and battery leasing solutions [1] - Jiadu Technology disposed of 7.6647 million shares of CloudWalk Technology, realizing a post-tax investment loss of 16.29 million yuan, which is 14.18% of the company's audited net profit for 2024 [1] Group 2 - Rongsheng Environmental's controlling shareholder and actual controller, Feng Ronghua, has been subjected to compulsory measures by the police, but this matter is unrelated to the company, which continues normal operations [2] - Chongqing Steel has terminated the absorption merger of its wholly-owned subsidiary, New Port Changlong, to leverage its independent operational advantages in logistics and supply chain services [3] - Ha Welding Huatong's products can be used in controllable nuclear fusion projects, but the revenue from this sector is currently minimal, and there are no significant changes in the company's operations [4] Group 3 - Xinhua Medical's controlling shareholder plans to increase its stake in the company by 100 million to 200 million yuan within the next 12 months [4] - Pingzhi Information signed a framework agreement for AI computing power technology services with China Telecom, totaling approximately 246 million yuan, which will not significantly impact the company's annual performance [5]

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-026 山东新华医疗器械股份有限公司 关于公司控股股东增持公司股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增持主体的基本情况：增持主体为山东新华医疗器械股份有限公司（以 下简称"公司"或"新华医疗"）控股股东山东颐养健康产业发展集团有限公司 （以下简称"山东健康集团"），本次增持计划实施前，山东健康集团持有新华医 疗无限售流通股 175,385,227 股，占公司总股本 606,677,919 股的 28.91%。 增持计划的主要内容：基于对新华医疗未来持续稳定发展的信心和长期 投资价值的认可，山东健康集团计划自本公告披露之日起 12 个月内通过上海证 券交易所交易系统以集中竞价交易方式等择机增持新华医疗 A 股股份，拟增持金 额不低于人民币 1 亿元（含本数），不超过人民币 2 亿元（含本数）。增持主体将 基于对新华医疗股票价格的合理判断，择机实施增持计划。 本次增持计划实施过程中，若山东健康集团持股比例拟达到或 ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-025 山东新华医疗器械股份有限公司 关于子公司产品获得三类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公司 山东新华血液技术有限公司近日收到国家药品监督管理局颁发的《中华人民共和国 医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：透析液过滤器 2、注册证编号：国械注准 20253100906 3、注册人名称：山东新华血液技术有限公司 4、注册人住所：山东省淄博市周村区新华大道 2009 号新华医疗科技园 E 区 E2-1-1#厂房 101 室 5、生产地址：山东省淄博市周村区新华大道 2009 号新华医疗科技园 E 区 E2-1-1#厂房 6、结构及组成：本产品主要由外壳、端盖、透析膜、密封胶、0 型密封圈与 密封塞组成。 9、批准日期：2025 年 4 月 30 日 10、有效期至：2030 年 4 月 29 日 11、同类产品相关 ...

Core Viewpoint - The controlling shareholder, Shandong Health Group, plans to increase its stake in Xinhua Medical (600587) by investing between 100 million to 200 million yuan within the next 12 months through the Shanghai Stock Exchange [1] Group 1: Shareholding and Investment Plan - Shandong Health Group currently holds 175 million unrestricted circulating shares of Xinhua Medical, accounting for 28.91% of the total share capital [1] - The funds for the share purchase will come from Shandong Health Group's own or self-raised funds [1] Group 2: Market Conditions and Risks - The share purchase plan may face risks due to changes in capital market conditions or other factors that could prevent the achievement of the expected investment [1]